Coeptis Therapeutics Holdings, Inc. (COEP) Financial Statements & Historical Data

Coeptis Therapeutics Holdings, Inc. (COEP) — Price $10.99 TechnologySoftware - Services — NASDAQ

Latest reported results:

Detailed financial statements for Coeptis Therapeutics Holdings, Inc. (COEP): income statement, balance sheet and cash-flow summary. Track margins, debt, liquidity and profitability trends year over year with up to 20 years of history.

Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates as a biopharmaceutical and technology company. The company is developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its therapeutic portfolio includes an allogeneic cellular immunotherapy platform; and DVX201, a clinical-stage, unmodified natural killer cell therapy technology.

Analysis Summary

Coeptis Therapeutics Holdings, Inc. reported revenue of $1.4M in the most recent fiscal year, growing at a 5-year CAGR of 113.5%.

Trailing-twelve-month margins: gross margin 86.7%, operating margin -9.6%, net margin -8.7%.

At the current price of $10.99, COEP has negative trailing earnings (P/E not meaningful) and an ROE of -69.09%. Market capitalisation stands at $39M.

Balance sheet quality for COEP: current ratio of 4.2, net cash position of $6.1M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.

Income Statement (10y)

Year2004200520182019202020212022202320242025
Revenue0000$30761$75000000$1.4M
Cost of Revenue0000$9642170000$180625
Gross Profit0000-$933456$75000000$1.2M
Research & Development0000$35430$20887$6.7M$2.3M$1.3M
Selling, General & Admin$10077$30830500$5.8M$14.1M$34.2M$13.8M$6.7M$11.9M
Operating Expenses$10077$30830500$5.9M$14.1M$34.2M$21.5M$10.1M$14.2M
Operating Income-$10077-$30800000-$6.9M-$14.0M-$34.2M-$21.5M-$10.1M-$13.0M
EBITDA$2.6M-$308000-$7070$171860-$8.7M-$12.8M-$36.4M-$20.1M-$9.4M-$10.4M
Interest Expense0000$148192$187133$218412$107685$396116$642379
Pre-tax Income$2.6M0-$7073-$2234-$9.2M-$13.4M-$37.6M-$21.3M-$10.9M-$12.3M
Income Tax0$3600000000000
Net Income$2.6M-$344000-$7073-$2234-$9.2M-$13.4M-$37.6M-$21.3M-$10.7M-$11.9M
EPS$1421.16$-184.81$-0.01$-0.00$-0.45$-13.16$-2.87$-0.83$-5.65$-2.81
EPS (Diluted)$1421.16$-184.81$-0.01$-0.00$-0.45$-13.16$-2.87$-0.83$-5.65$-2.81
Shares Outstanding (Diluted)$1863$1863$539062$10.8M$20.4M$1.0M$14.3M$25.7M$1.9M$4.2M

Income Statement (Quarterly)

Year2025-Q32025-Q42026-Q12026-Q2
Revenue$237441$862049$113771$1.6M
Gross Profit$192286$816892$68615-$608438
Operating Income-$2.5M-$2.0M-$3.9M-$13.8M
EBITDA-$2.5M-$876404-$3.5M-$13.8M
Net Income-$2.7M-$1.6M-$4.0M-$13.7M
EPS$-0.58$-0.29$-0.65$-0.28
EPS (Diluted)$-0.58$-0.29$-0.65$-0.28

Balance Sheet (10y)

Year2004200520182019202020212022202320242025
Cash & Equivalents$383$1535580$505$202965$2.2M$3.8M$1.5M$532885$5.7M
Short-term Investments000000000$676596
Receivables0000$217860$8075$389780$7348
Inventory0000000000
Total Current Assets$383$1535580$505$224751$2.2M$3.9M$1.7M$1.1M$7.4M
Property, Plant & Equipment0000$73732$31851$71456$108877$59783$18399
Goodwill0000000000
Intangible Assets$465380000$4.6M$3.6M$2.6M$541875$361250
Total Assets$46921$153558$80000$171545$300484$6.8M$7.9M$8.1M$8.9M$19.8M
Accounts Payable$215935$552150$450$1.6M$134092$99021$1.4M$1.3M$888755
Short-term Debt$95000$650000$62073$152644$1.9M$2.4M$1.9M$1.0M$1.2M$118875
Total Current Liabilities$310935$705215$62073$155852$5.3M$2.8M$2.2M$3.0M$4.5M$1.8M
Long-term Debt0000$150000$1.6M$150000$150000$150000$150000
Total Liabilities$310935$705215$62073$155852$5.4M$4.4M$3.5M$3.8M$5.0M$2.1M
Retained Earnings-$2.9M-$3.3M-$7073-$9307-$14.1M-$27.6M-$66.1M-$87.4M-$98.2M-$110.0M
Total Equity-$264014-$551657$17927$15692-$5.1M$2.4M$4.5M$4.3M$3.2M$17.2M
Total Debt$95000$650000$62073$152644$2.1M$4.1M$2.1M$1.2M$1.4M$268875
Net Debt$94617$496442$62073$152139$1.9M$1.9M-$1.7M-$244908$866168-$6.1M
Working Capital-$310552-$551657-$62073-$155347-$5.1M-$585384$1.8M-$1.2M-$3.5M$5.6M

Balance Sheet (Quarterly)

Year2025-Q32025-Q42026-Q12026-Q2
Cash & Equivalents$4.9M$5.7M$5.2M$15.5M
Total Assets$16.3M$19.8M$19.8M$134.5M
Total Liabilities$3.3M$2.1M$2.2M$2.0M
Total Equity$12.5M$17.2M$20.8M$132.5M
Total Debt$279865$268875$3433530

Cash Flow (10y)

Year200420052019202020212022202320242025
Net Income$2.6M-$344305-$2234-$9.2M-$13.4M-$37.6M-$21.3M-$10.9M-$11.9M
Depreciation & Amortization000$323428$447413$1.0M$1.0M$1.0M$1.2M
Stock-based Compensation0000$1.9M0$477503$1.1M$1.2M
Change in Working Capital-$1.1M-$72720$450$2.7M-$3.0M-$550335$1.7M-$125262-$1.5M
Operating Cash Flow$1.6M-$417025-$90066-$3.1M-$4.5M-$3.9M-$7.2M-$6.6M-$8.6M
Capital Expenditure0000-$1.8M0000
Acquisitions000000000
Stock Repurchased0000-$2471650000
Dividends Paid000000000
Free Cash Flow$1.6M-$417025-$90066-$3.1M-$6.2M-$3.9M-$7.2M-$6.6M-$8.6M

Cash Flow (Quarterly)

Year2025-Q32025-Q42026-Q12026-Q2
Operating Cash Flow-$2.2M-$1.7M-$1.8M$1.6M
Capital Expenditure-$30-$30
Free Cash Flow-$2.2M-$1.7M-$1.8M$1.6M
Dividends Paid0000
Stock-based Compensation0$213905$1.4M$5.6M

Growth & Margins (10y)

Year2004200520182019202020212022202320242025
Revenue Growth (YoY)+143.8%-100.0%
Net Income Growth (YoY)-113.0%+97.9%+68.4%-409760.6%-46.9%-179.4%+43.4%+49.8%-11.6%
EPS Growth (YoY)-113.0%+100.0%+98.5%-224900.0%-2824.4%+78.2%+71.1%-580.7%+50.3%
Shares Change (YoY)+0.0%+28835.2%+1900.0%+89.6%-95.0%+1298.8%+79.7%-92.5%+120.0%
FCF Growth (YoY)-126.8%+78.4%-3382.0%-99.0%+37.9%-86.8%+8.2%-29.4%
Gross Margin-3034.5%100.0%86.7%
Operating Margin-22305.5%-18727.9%-956.9%
EBITDA Margin-28232.7%-17086.3%-763.9%
Net Margin-29765.9%-17932.4%-874.3%
FCF Margin-10195.1%-8319.3%-631.2%
Effective Tax Rate0.0%-0.0%-0.0%-0.0%-0.0%-0.0%-0.0%-0.0%-0.0%

Per-Share Data (10y)

Year2004200520182019202020212022202320242025
FCF Per Share$834.05$-0.77$-0.01$-0.15$-6.11$-0.27$-0.28$-3.45$-2.03
Dividends Per Share$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00
Shares Outstanding (Basic)$1863$1863$539062$10.8M$20.4M$1.0M$14.3M$25.7M$1.9M$4.2M

What to look at in Technology companies

Profitability

Return on Equity-69.09%
Return on Invested Capital-71.70%
Return on Assets-60.06%
Gross Margin86.75%
Operating Margin-956.94%
Net Margin-874.29%

Financial Health

Debt / Equity0.02
Current Ratio4.16
Piotroski F-Score6
Altman Z-Score7.84

Key Ratios (10y)

Year2004200520182019202020212022202320242025
P/E0.14-1.07-15000.00-990000.00-452.89-15.20-10.67-18.89-0.97-5.07
P/B-1.40-0.675953.83136036.67-809.9686.9698.3093.383.323.50
P/S0.000.000.000.00135427.192725.330.000.000.0044.27
Gross Margin0.0%0.0%0.0%0.0%-3034.5%100.0%0.0%0.0%0.0%86.7%
Operating Margin0.0%0.0%0.0%0.0%-22305.5%-18727.9%0.0%0.0%0.0%-956.9%
Net Margin0.0%0.0%0.0%0.0%-29765.9%-17932.4%0.0%0.0%0.0%-874.3%

Related companies: CUE · EQ · IPSC · KPTI · MDCX · NRXP · OSTX

Explore sector: Technology · Software - Services

More sections of COEP: Overview · Valuation · Statistics · Estimates · Technical · Ownership · News · Events

Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks